Opinion|Videos|February 20, 2025
Adherence and Time Spent Receiving IV Iron Infusions
Panelists discuss how IV iron formulations requiring fewer infusion visits tend to have better adherence rates, while the ongoing nursing shortage has created additional challenges in scheduling and administering IV iron treatments, leading clinicians to favor products that can achieve iron repletion in fewer sessions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Adherence to recommended treatment dosing tends to decline as the number of separate recommended infusion visits increases. Could you share your clinical experience on how variations in dosing among different agents influence patient adherence?
- Has the recent nursing shortage impacted your practice in patients requiring IV iron formulations?
Advertisement
Related to this article
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
IVF Beats IUI for Early Live Births in Unexplained Infertility
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5